Sirona Biochem Pitch Deck Teardown: Licensing a Proprietary

Slide-by-Slide Analysis

Slide 1: Title Slide

The cover slide introduces Sirona Biochem with the tagline 'Advancing Chemistry. Enhancing Health.' It identifies the company's ticker symbol (TSX-V: SBM) and dates the presentation to March 2022. The imagery is standard laboratory-focused biotech branding, featuring glassware and a scientist in the background.

Slide 2: Investment Highlights and Fundamental Data

This slide serves as a summary of the company's value proposition and public market standing. It notes that the technology is based on 20 years of research by an 'award winning CSO' through a French subsidiary, TFChem. Key milestones mentioned include a manufacturing agreement in China and the 2021 launch of a product with Rodan + Fields. The 'Fundamental Data' table provides a snapshot of the stock's performance as of March 3, 2022, listing 250,251,526 shares outstanding and a market cap of $52,553,000. The share price is noted at $0.21, with a year high of $0.56 and a low of $0.14.

Slide 3: The Potential of Carbohydrate Compounds

Sirona uses this slide to validate the market category. They argue that carbohydrate compounds have 'immense commercial potential' by citing historical successes. Specifically, they point to Tamiflu (anti-viral) with sales exceeding $2.9 Billion USD during the H1N1 outbreak, and Lovenox (blood thinner) with $1.73 Billion USD in sales in 2018. This is a classic 'social proof' slide for a scientific niche, linking Sirona's focus to proven multi-billion dollar markets.

Slide 4: Business Model

The business model is described as a pure-play licensing strategy. Sirona develops and patents compounds, then licenses them to 'leading global companies.' The revenue streams are clearly defined: up-front fees, milestone fees, and ongoing royalty payments. This model is attractive to investors because it reduces the capital expenditure required for manufacturing and distribution, shifting those costs to the licensing partners.

Slide 5: TFC-1067 Clinical Study

This slide provides technical validation for their lead compound, TFC-1067. It details a 12-week double-blind study with 48 participants conducted by Dr. Zoe Draelos in the USA. The key claim is 'superiority to the gold standard, hydroquinone' for treating hyperpigmentation. The slide asserts that the compound achieved its endpoint of lightening skin without safety issues, providing 'strong evidence' for its use as a replacement for existing treatments.

Slide 6: About Us (Transition)

A simple transition slide titled 'About Us' with the company logo and a dark, stylized background of lab equipment.

Slide 7: Management

The management slide profiles two key executives. Christopher Hopton, CFO, is highlighted for his 28 years of experience in financial management, including roles at Central Resources Corp. and Canadian Airlines. Michelle Seltenrich, VP of Operations, is credited with 21 years of experience in biotech, specifically in R&D lab management and M&A. Both profiles emphasize their education at Simon Fraser University and the University of British Columbia. Notably, a CEO or CSO profile is absent from this specific slide, which is an unusual omission for a management summary.

Slide 8: Contact Information

The final slide provides the company website and a general inquiry email address. It also reiterates the trading symbols for the TSX-V (SBM), Frankfurt (ZSB), and US-OTC (SRBCF) markets, set against an architectural background of a modern office building.

What Sirona Biochem Does Well

The deck is highly effective at articulating a clear, low-risk business model. By focusing on licensing rather than full-cycle production, Sirona positions itself as a high-margin intellectual property house. The use of Slide 3 to benchmark their technology against multi-billion dollar drugs like Tamiflu provides immediate context for the 'why now' and the scale of the opportunity. Furthermore, the inclusion of specific clinical trial parameters (Slide 5) adds a layer of scientific credibility that is often missing from early-stage biotech decks. The 'Fundamental Data' section on Slide 2 is also a transparent way to handle the realities of being a micro-cap public company, providing investors with the necessary liquidity and valuation metrics upfront.

What is Missing from the Deck

The most glaring omission in the provided slides is the absence of a CEO or Chief Scientific Officer (CSO) in the management section. While Slide 2 mentions an 'award winning CSO,' the management slide (Slide 7) only lists the CFO and VP of Operations. In biotech, the scientific pedigree of the lead researcher is often the primary driver of investor confidence. Additionally, there is no 'Ask' slide. While this is common for general investor relations decks for public companies, a fundraising deck usually specifies how much capital is being sought and exactly how it will be deployed (e.g., '50% to Phase II trials, 30% to IP filing'). Finally, there is no detailed competitive landscape. While they mention being better than the 'gold standard' hydroquinone, they do not address other emerging biotech competitors in the carbohydrate stabilization space.

Instructions for Founders

Founders in the deep-tech or biotech space should look at Slide 4 as a template for explaining a licensing model. It is concise and uses industry-standard terminology (up-front, milestones, royalties) that investors understand. The 'Investment Highlights' on Slide 2 is also a strong example of how to mix technical achievements with commercial milestones; notice how they lead with 'Proprietary technology' but immediately follow with 'Signed commercial-scale manufacturing agreement.' This balances scientific promise with business execution. However, founders should avoid the mistake of omitting the lead scientist from the team slide. In any technical venture, the person holding the 'secret sauce' must be front and center to validate the technical risk.